Meraggra Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 22.27%
- Profit Growth 128.78%
- Ebitda 143.90%
- Net Worth 13.48%
- Total Assets 33.66%
About Meraggra Pharmaceutical
Meraggra Pharmaceutical Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 January 2019 (Six years and one month 9 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Madhukar Rangari, Premdas Meshram, Manish Ganvir, and Two other members serve as directors at the Company.
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304MH2019PTC319738
- Company No.
319738
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Meraggra Pharmaceutical?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhukar Rangari  | Director | 16-Jan-2019 | Current |
| Premdas Meshram | Director | 05-Feb-2019 | Current |
| Manish Ganvir | Director | 19-Jul-2019 | Current |
| Laxman Ramteke | Director | 16-Jan-2019 | Current |
| Pravin Gajbhiye | Director | 16-Jan-2019 | Current |
Financial Performance of Meraggra Pharmaceutical.
Meraggra Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 22.27% increase. The company also saw a substantial improvement in profitability, with a 128.78% increase in profit. The company's net worth Soared by an impressive increase of 13.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meraggra Pharmaceutical?
Unlock access to Meraggra Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Meraggra Pharmaceutical?
Unlock and access historical data on people associated with Meraggra Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meraggra Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meraggra Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.